AVE 33.3% 0.2¢ avecho biotechnology limited

financials out now, page-30

  1. 120 Posts.
    lightbulb Created with Sketch. 1
    @turps

    OK... If we don't need phase 3 that's brilliant. But I definitely remember that early talk around the time of the last raise was that we'd do 'combined 2/3 trials. But then the mood and consensus turned towards doing phase 2 and 3 separately.Yet now somehow phase 3 isn't necessary? Well if it isn't, brilliant, I look forward to a much higher SP
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.